• Sticky Webs, A Tiny Molecular Weapon, Obesity Paradox N/A: COVID-19 Updates

    Bio-IT World New drug targets, reconstructing viral spread and lineage, monitoring mutations, reasons to focus on T-cell responses, DNA webs as culprits of tissue damage, a very tiny neutralizing agent, explaining paradoxical risk in people with obesity and diabetes, and the value of heparan. Plus, a new vaccine candidate heading to human trials, coronaviruses are being profiled, and a deep dive on how SARS-CoV-2 weakens the immune system.

    Sep 17, 2020

  • Targeted Protein Degradation: Why Just Inhibit What Can Be Destroyed?

    Bio-IT World Disease treatment through targeted protein degradation takes a range of approaches: from small molecules similar to thalidomide that act as “molecular glue” degraders to more advanced “beyond rule of 5” proteolysis-targeting chimeras (PROTACs) with bifunctional moieties that encourage protein interaction with its E3 ubiquitin ligase.

    Sep 17, 2020

  • Continuous Software Validation Critical for Balancing Digital Transformation and Compliance

    Bio-IT World  The adoption of cloud technology in the life science industry has become increasingly pervasive as firms move forward with digital transformation initiatives aimed at creating operational efficiencies and delivering the next wave of biomedical innovations. As a result, cloud vendors are playing a more important role than ever before, especially for life sciences companies that produce FDA-regulated products.

    Sep 15, 2020

  • VAST Data Launches LightSpeed Storage Architecture

    Bio-IT World VAST Data has launched its next generation storage architecture, LightSpeed, which combines the light-touch of VAST’s simple NAS appliance experience with leadership-class performance for GPU-based and AI Processor-based computing, taking the guesswork and configuration out of scaling up AI infrastructure.

    Sep 15, 2020

  • Follow the Money: Alzheimer’s Meds, Single Cell Multi-Omics Technology

    Bio-IT World | NIH contracts to explore radiation countermeasures, Alzheimer’s medication, and convalescent plasma, Mission Bio gets $70M for single cell multi-omics technology, and more.

    Sep 11, 2020

  • No Cytokine Storm, ‘Bursty’ Disease Spread: Biomarkers For Elevated Risk: COVID-19 Updates

    Bio-IT World  | Japanese researchers argue there is no cytokine storm, computer-designed protective proteins, ELISA test for antibodies, COVID-19’s impact on Black and Hispanic communities, a “burstier” model of disease spread, and new biomarkers for elevated risk. Plus, the International Vaccine Institute preps with Gates money, 3M funds vaccine researcher, and more.

    Sep 10, 2020

  • Beyond the Rule of 5: Vastly Expanding Targetable Drugs

    Bio-IT World | At the Drug Discovery Chemistry Virtual conference, researchers from industry and academia provide a glimpse into the expanse of pharmaceuticals available beyond Lipinski’s Rule of 5, an endeavor that will hopefully enable the development of much more specific agents with vastly expanded targetable options.

    Sep 8, 2020

  • Computational Tool Could Improve Clinical Success Rate Of Drugs

    Bio-IT World  A newly developed translatable components regression (TransComp-R) model, developed by researchers from Purdue University and the Massachusetts Institute of Technology (MIT), recently identified an overlooked biological mechanism possibly responsible for resistance to the drug infliximab commonly prescribed to patients with inflammatory bowel disease (IBD).

    Sep 8, 2020

  • Mouse Models, Machine Learning, Triggering Proteins: COVID-19 Updates

    Bio-IT World   A potential new screening approach, improving immune response to vaccines, new mouse models of SARS-CoV-2, exploring ACE2 receptor activity, a protein that may trigger blood clots, the importance of placenta tissue, hopeful signs that a single vaccine can do the job, and a bioengineering technique to boost production of proteins that prompt antibody development. Plus, machine learning to help identify drug combinations that can be repurposed as potential therapies.

    Sep 3, 2020

  • Phil Baran on the Quest to Make Chemistry Boring Again

    Bio-IT World | Phil Baran of Scripps Research is dedicated to simplifying chemical synthesis, not to create techniques that are “gimmicky” but will instead become the standard processes of the future. Maybe, “fifty years from now,” he predicts, “we’ll look back in curiosity at chemists of our age who had stages in their syntheses instead of making everything in 1-3 steps.”

    Sep 2, 2020

  • Truth Challenge v2: Latest Challenge Results From Genome In A Bottle

    Bio-IT World  PrecisionFDA and The Genome in a Bottle (GIAB) consortium have announced the results of the Truth Challenge V2: Calling Variants from Short and Long Reads in Difficult-to-Map Regions such as segmental duplications, and the Major Histocompatibility Complex (MHC).

    Sep 2, 2020

  • A Virtual Feast: A Preview of Bio-IT World 2020

    Bio-IT World | The 2020 Bio-IT World Conference & Expo Virtual includes three days full of content, networking, and interaction across 16 tracks, plenary session, workshops, posters, awards, and happy hours. And for the first time ever, many presentations will be available on demand after their first showing. We are already building our agenda.  

 

Sep 1, 2020

  • Racial Impacts of COVID-19, Neutralizing Antibodies, More

    Bio-IT World | Racial segregation of COVID-19 is following HIV patterns, more data on neutralizing antibodies, four months of data from Italy's use of hydroxychloroquine, and a computer model for school launches. Plus, an award from the UK government for vaccine development. 

    Aug 28, 2020

  • UK Biobank Contracts With DNAnexus, AWS to Build Data Analysis Platform

    Bio-IT World  UK Biobank, a long-term study of health data from 500,000 UK volunteers, announced today that it is developing its own cloud-based Data Analysis Platform to make its extensive medical data available to a broader range of researchers around the world. Funding for the Data Analysis Platform has come from Wellcome, and it will be developed over the next three years by DNAnexus in collaboration with Amazon Web Services (AWS).

    Aug 26, 2020

  • Vertiv, Pure Storage, And More: News From August 2020

    Bio-IT World   August featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including Vertiv, Pure Storage, and more.

    Aug 25, 2020

  • Beetle Viruses, Nitrate Supplements, Missing Sense of Smell: COVID-19 Updates

    Bio-IT World | How a beetle virus is informing SARS-CoV-2 research, plus nitrate supplementation for aid breathing, new small molecules active against the virus, and a theory for why COVID-19 patients lose their sense of smell. Plus, $9.8 million from DOD for vaccine research and virus-like particles for vaccine development.

    Aug 21, 2020

  • Combined Monogenic, Polygenic Risk Scores Could Change Medical Understanding of Disease

    Bio-IT World | In a paper published today in Nature Communications, IBM and the Broad Institute reported the first results of their collaboration to develop predictive models for cardiovascular disease.

    Aug 20, 2020

  • Bringing Peer Review To Early COVID-19 Research, More News

    Bio-IT World | New insights into the SARS-CoV-2 spike protein, a daily aerosol protectant, a look a death rates in 1918 and now, and a journal dedicated to publishing COVID-19 research with visible peer review. Plus new funding from NIH and the American Heart Association to enable further research on SARS-CoV-2 and COVID-19.

    Aug 18, 2020

  • Bringing Peer Review To Early COVID-19 Research, More

    Bio-IT World | New insights into the SARS-CoV-2 spike protein, a daily aerosol protectant, a look a death rates in 1918 and now, and a journal dedicated to publishing COVID-19 research with visible peer review. Plus new funding from NIH and the American Heart Association to enable further research on SARS-CoV-2 and COVID-19.

    Aug 14, 2020

  • Five Steps to Commercialization Success and Common Challenges You Can Easily Avoid

    Bio-IT World Contributed Commentary | It’s no surprise that advancements in novel technologies and the advent of big data have propelled significant breakthroughs in pharmaceutical development. The last decade has not only seen an increase in new chemical and biological entities but also significantly more innovative medicines reaching the market. Looking to the future, we also expect to see an intensified focus on neglected diseases as new and emerging biopharma companies (EBP) drive new medicine launches. However, to get there, organizations reaching for “first-in-market” status or securing key market areas depends on their ability to swiftly commercialize these new technologies and therapeutics.

    Aug 17, 2020